MedTrace Logo

Candesartan in the Prevention of Relapsing Atrial Fibrillation

NCT00130975 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2007-01-04

No results posted yet for this study

Summary

The purpose of this study is to test the hypothesis that treatment with the angiotensin II type 1 receptor antagonist candesartan may reduce the recurrence rate of atrial fibrillation after electrical cardioversion.

Conditions

Interventions

DRUG

Candesartan

Sponsors & Collaborators

  • Helse Ost

    collaborator UNKNOWN

  • Ullevaal University Hospital

    collaborator OTHER

  • AstraZeneca

    collaborator INDUSTRY

  • Asker & Baerum Hospital

    lead OTHER

Principal Investigators

  • Arnljot Tveit, MD · Asker & Baerum Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-04-30
Completion
2005-09-30

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00130975 on ClinicalTrials.gov